- Safety aspects of AL001 development may qualify for (505)(b)(2) pathway for FDA approval
- Alzamend’s recently completed a Phase IIA Study of AL001 in Alzheimer’s and healthy patients that identified a candidate dose that is unlikely to require therapeutic drug monitoring
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.